NDMA had previously been found in some blood pressure medicines from a class of drugs known as angiotensin II receptor blockers, or ARBs.
Four types of Zantac have been recalled by GlaxoSmithKline, the drugs manufacturer, including; 150mg (10ml) Syrup, Zantac 50mg (2ml) Injection, Zantac 150mg Tablets and Zantac 300mg Tablets.
However they suggested sufferers don't cease taking their remedy and search their medical doctors recommendation.
The government agency said it was also investigating other potentially impacted products and will provide further updates as the investigation progresses.
Healthcare professionals have been told to stop supplying the products immediately, quarantine all remaining stock and return it to their supplier.
"Patients should keep taking their current medicines but should speak to their doctor or pharmacist if they are concerned and should seek their doctor's advice before stopping any prescribed medicines".
Dr Andrew Gray, from the MHRA, said: "Whilst this action is precautionary, the MHRA takes patient safety very seriously".
"GSK is continuing with investigations into the potential source of the NDMA", he said, adding that the investigations include continued engagement with its suppliers and with external laboratories to conduct tests on finished product batches of Zantac.
A decision for the drug to be reviewed was made by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on September 13.
The company led-global recall cites possible contamination with an impurity N-nitrosodimethylamine (NDMA) which has genotoxic and carcinogenic potential.
GSK, the original developer of the antacid Zantac, in an emailed comment today pointed out that it does not sell Zantac prescription or over-the-counter products in the U.S. Sanofi has U.S. rights to the brand.